An Eye-Opener for investors: VistaGen Therapeutics, Inc. (VTGN) roared in the late trading
VistaGen Therapeutics, Inc. (VTGN) surged as high as 24.73% to $1.16 in the after-market as a biopharmaceutical company dedicated to developing new medicines for anxiety, depression, and other disorders of the central nervous system, announced it had commenced an underwritten public offering of its common stock, equal to $0.001 per share, and its Series D […]
